Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.
JSON
Pfankuchen DB, Baltes F, Batool T, Li JP, Schlesinger M, Bendas G
Oncotarget 8 (40) 67553-67566 [2017-09-15; online 2017-06-28]
Low molecular weight heparin (LMWH), the guideline based drug for prophylaxis and treatment of cancer-associated thrombosis, was recently shown to sensitize cisplatin resistant A2780cis human ovarian cancer cells for cisplatin cytotoxicity upon 24 h pretreatment with 50 μg × mL
PubMed 28978053
DOI 10.18632/oncotarget.18738
Crossref 10.18632/oncotarget.18738
pii: 18738
pmc: PMC5620193